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Phage therapy recently passed a key milestone with success of the first regulated clinical
trial using systemic administration. In this single-arm non-comparative safety study,
phages were administered intravenously to patients with invasive Staphylococcus
aureus infections with no adverse reactions reported. Here, we examined features of 78
lytic S. aureus phages, most of which were propagated using a S. carnosus host modified
to be broadly susceptible to staphylococcal phage infection. Use of this host eliminates
the threat of contamination with staphylococcal prophage— the main vector of S. aureus
horizontal gene transfer. We determined the host range of these phages against an
international collection of 185 S. aureus isolates with 56 different multilocus sequence
types that included multiple representatives of all epidemic MRSA and MSSA clonal
complexes. Forty of our 78 phages were able to infect > 90% of study isolates, 15 were
able to infect > 95%, and two could infect all 184 clinical isolates, but not a phage-resistant
mutant generated in a previous study. We selected the 10 phages with the widest host
range for in vitro characterization by planktonic culture time-kill analysis against four
isolates:- modified S. carnosus strain TM300H, methicillin-sensitive isolates D329 and
15981, and MRSA isolate 252. Six of these 10 phages were able to rapidly kill, reducing
cell numbers of at least three isolates. The four best-performing phages, in this assay,
were further shown to be highly effective in reducing 48 h biofilms on polystyrene formed
by eight ST22 and eight ST36 MRSA isolates. Genomes of 22 of the widest host-range
phages showed they belonged to the Twortvirinae subfamily of the order Caudovirales in
three main groups corresponding to Silviavirus, and two distinct groups of Kayvirus.
These genomes assembled as single-linear dsDNAs with an average length of 140 kb and
a GC content of c. 30%. Phages that could infect > 96% of S. aureus isolates were found
in all three groups, and these have great potential as therapeutic candidates if, in future
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studies, they can be formulated to maximize their efficacy and eliminate emergence of
phage resistance by using appropriate combinations.
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INTRODUCTION
Staphylococcus aureus is one of the major causes of both hospital-
and community-acquired infections globally. It is an extremely
versatile pathogen, causing a broad spectrum of diseases ranging
in severity from minor skin and soft-tissue infections to life-
threatening invasive infections (Lowy, 1998). Hospitalized
patients are particularly prone to S. aureus infections because
of the presence of compromised immune systems and surgical
site infections caused by the implantation of indwelling medical
devices (Brandt et al., 1999). S. aureus is commonly resistant to
penicillin and methicillin-resistant S. aureus (MRSA) infections,
resistant to all beta-lactam antibiotics, are most frequently
treated with intravenous vancomycin, the antibiotic of “last
resort” for resistant staphylococcal infections. However,
resistance to this antibiotic (Centers for Disease Control and
Prevention, 2002) and newer agent, such as linezolid (Tsiodras
et al., 2001) and daptomycin (Skiest, 2006), have emerged, and
there is a great and ever-increasing need for novel antibiotics and
other therapeutic strategies for treating this pathogen.
Phage therapy exploits the natural ability of lytic bacteriophages
(phages) to invade, multiply intracellularly, and then kill their host.
Obligately, lytic phage are regarded as the most appropriate
candidates in human health because they are capable of rapidly
killing their host, greatly reducing the chances of bacteria developing
phage resistance (Skurnik et al., 2007; Cui et al., 2017b). They also
lack the required genetic factors for genome incorporation found in
temperate phages. Despite widespread use in the 1930s, phage
therapeutics were largely eclipsed by the discovery and clinical
development of broad-spectrum antibiotics in western countries.
However, phage therapy continues to be used at The G. Eliava
Institute of Bacteriophage, Microbiology, and Virology in Tbilisi,
Georgia and the Institute of Immunology and Experimental
Therapy in Wroclaw, Poland, and these have become major
centers for the development and application of phage therapy
(Summers, 2001; Kutter et al., 2010). Success rates exceeding 85%
have been reported in treating antibiotic-resistant infections caused
by pathogens, including S. aureus, Pseudomonas aeruginosa,
Klebsiella pneumoniae, and Escherichia coli in Poland (O’Flaherty
et al., 2009) in studies involving large patient numbers. To date,
there have been three early-stage clinical trials of phages for the
treatment of S. aureus infections. In 2009, Rhoads et al. reported
safety in a trial of phages against venous leg ulcers (Rhoads et al.,
2009) and more recently McCallin et al. (2018) demonstrated the
safety of a broad-spectrum phage cocktail in a placebo-controlled
study, including nasal and oral administration. A recent study in
Australia demonstrated safety of a good manufacturing practice —
quality three-phage cocktail administered intravenously to 13
patients with invasive S. aureus infections (Petrovic Fabijan et al.,
2020). This study marked a milestone in phage therapy, the first
regulated clinical trial of systemically administered phages.
Most reports in the literature regarding lytic staphylococcal
phages show that these are typically members of the Twortvirinae
subfamily, which currently comprises five genera representing
distinct lineages — Kayvirus, Sepunavirus, Silviavirus,
Twortvirus, and unclassified Twortvirinae. These phages display
a broad host range, infectingmost S. aureus isolates and even those
of other staphylococcal species (Lobocka et al., 2012). Studies on
these group of phages and also their lytic enzymes hold promise
for future clinical development alone or in combination with
antibiotics (Berryhill et al., 2021) especially as comparative
genomic analysis show little similarity between phages from
different lineages in gene complement or in their lytic gene
sequences (O’Flaherty et al., 2005a; Synnott et al., 2009; Lobocka
et al., 2012). These may therefore represent an important and
diverse source of phages for traditional therapy or development of
treatments based on novel antimicrobial enzymes.
Here, we report on the isolation and characterization of 78 lytic
phages with broad host range against a diverse collection of S.
aureus. These 185 isolates include members of all globally
disseminated MRSA and methicillin-sensitive lineages, including
multiple isolates of clonal complexes (CCs) 1, 5, 8, 22, 30, 45, 59,
and CC80 containing the main MRSA lineages (Chatterjee and
Otto, 2013). Wherever possible, we isolated and propagated phages
on a modified S. carnosus isolate that is avirulent (Rosenstein et al.,
2009), containing none of the virulence genes associated with S.
aureus prophages that could potentially compromise the safe
production of phages for therapeutic use. We examined the in
vitro characteristics of selected phages in planktonic and biofilm
culture and characterized the genomic similarity and taxonomy of
22 phages with some of the broadest host ranges.
MATERIALS AND METHODS
Bacterial Strains
A modified S. carnosus strain, TM300H, a hybrid strain derived
from TM300H expressing both its native glycerol-phosphate
(GroP)- and S. aureus ribitol-phosphate (RboP)-type wall
teichoic acids, was used for phage isolation and propagation. S.
carnosus is a non-virulent staphylococcal species used in meat
production, and as such, we considered it a benign propagating
host for phage production. TM300H was transformed with a
chloramphenicol resistance plasmid encoding polyribitol-
phosphate (RboP) repeating units of S. aureus wall teichoic
acid to promote phage adsorption (Winstel et al., 2013). This
required supplementation of growth medium with 10 mg/ml
chloramphenicol. The methicillin-sensitive isolate D329 was
used as an alternative host for phage propagation where this
was not possible using TM300H. S. aureus isolate 15981
(obtained from Prof ATA Jenkins, University of Bath, UK) was
also included in this study as it is a very strong biofilm producer
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and has been used in several studies of S. aureus virulence and
biofilm regulation including those by Valles et al. (2003) and
Toledo-Arana et al. (2005). All bacterial isolates were cultured in
tryptone soy broth (TSB) or agar (TSA) and stored at −80°C in
TSB containing 25% (v/v) glycerol. One hundred eighty-five
genetically diverse isolates of S. aureus from our collection,
including isolates from 13 published studies of human and
animal carriage and disease, were used in this study (Table 1).
They comprised 126 MRSA and 59 MSSA isolates from 14
different countries with 58 different multilocus sequence types
(Enright et al., 2000). This collection contains multiple
representative isolates of all major MRSA and MSSA lineages
(Enright et al., 2002; Feil et al., 2003; Holden et al., 2013),
including those associated with community-onset (Vandenesch
et al., 2003) and livestock-associated (van Belkum et al., 2008)
MRSA infections. Table 1 shows the MLST sequence type and
clonal complex of each isolate, as well as a reference to the
original study where the isolate was first characterized using
MLST, and for MRSA isolates — SCCmec typing. Further
information on study isolates are available from the cited
source and, in most cases, from the PubMLST website at
https://pubmlst.org/organisms/staphylococcus-aureus.
Phage Isolation, Propagation, and Host
Range Determination
Sewage effluent samples were collected from various process
tanks at Davyhulme and Eccles wastewater treatment works,
Manchester, England. Organic matter was removed from
samples by centrifugation at 3,000g for 30 min. 10-ml aliquots
of supernatant were filtered (0.22 mm pore size), before being
combined with 10 ml of double-strength TSB and 100 ml of
exponentially growing bacterial cultures, followed by incubation
at 37°C, in an orbital incubator at 150 rpm for 24 h. Bacterial
debris were removed by centrifugation (3,000g, 30 min), and
supernatants were filtered (0.22 mm) and stored at 4°C. This
supernatant was used to check the presence of lytic phages using
the double-agar overlay method (Kropinski et al., 2009). Isolated
single plaques were picked into SM buffer (50 mM Tris-HCl, 8
mMMgSO4, 100 mM NaCl, and 0.01% gelatin, pH 7.5) in sterile
distilled water, and successive rounds of single plaque
purification were carried out until purified plaques were
obtained. Purified phage suspensions were maintained at 4°C.
S. carnosus strain TM300H was used for phage propagation
whenever possible; however, for some phages, the methicillin-
sensitive S. aureus isolate D329 was used (Table 1).
Phage host range was determined by spot test, 100 ml of
log phase bacterial culture was mixed with 10 ml soft agar,
the mixture poured onto 10 ml TSA plates and 10 ml
phage lysate (~106 pfu/ml) spotted onto the plate prior to
overnight incubation at 37°C. Bacterial strains were classed
as wholly sensitive to a particular phage if spot test resulted in
a clear plaque, intermediately sensitive if plaques showed
evidence of clearing but were hazy or turbid and resistant if
no clearing was present. All host range assays were performed
in triplicate.
A collection of 32 uncharacterized S. aureus phages collected
in previous studies was also included in this study.
In Vitro Growth Experiments
Growth Kinetics in Planktonic Culture
The growth rate of each bacterial isolate in liquid culture was
studied in 96-well flat-bottomed microtiter plates by measuring
absorbance of each well using the method of Alves et al. (2014).
Briefly, bacterial growth was measured by absorbance (600 nm)
over 19 h at 37°C, with shaking, using a microplate reader
(FLUOstar Omega, BMG LABTECH). The plate reader provided
absorbance data points every 180 s following a 10-s agitation at
200 rpm. Data points after every 30 min were used for analysis.
Time-Kill Assays
Time-kill assays were performed to determine the sensitivity of
planktonic bacterial cells to phage infection and to investigate the
frequency of phage-resistant bacterial mutants using the method
described in Alves et al. (2014). Briefly, 200 µl of 1:100 dilutions
of overnight bacterial cultures were added to wells of 96-well
microtiter plates. Dilutions were made using TSB. After 2 h of
incubation at 37°C, phage lysate, at an MOI of 0.1, was added,
and the microplates were incubated for a further 17 h.
Experiments were performed in triplicate.
Formation and Treatment of S. aureus Biofilms
Biofilm assays followed a standard 96-well plate method as
described previously (Alves et al., 2014). Briefly, 200 µl of 1:100
dilutions of overnight bacterial culture, made using TSB
supplemented with 1% D-(+)-glucose (TSBg), were added to
microtiter plates. Microtiter plates with lids were sealed with
Parafilm were wrapped in moistened paper towel, then placed in
a sealed plastic box to maintain humidity. Plates were incubated at
37°C for 48 h without agitation to allow biofilm formation. After
24 h, 50 ml of spent medium was withdrawn and replaced with 50
ml of fresh TSBg. Plates were then incubated for a further 24 h at
37°C. Biofilms were washed three times with PBS before air drying
and staining with 0.1% (w/v) crystal violet (CV). Stained
biofilms were rinsed with PBS, air dried then solubilized in 200
ml of 30% (v/v) glacial acetic acid. Biofilm mass was measured
spectrophotometrically using a FLUOstar plate reader at
absorbance of 590 nm. Enumeration of S. aureus cells recovered
from 48-h biofilms was performed by washing with PBS to remove
non-adherent bacteria and residual media. Biofilms were then
resuspended in 200-µl PBS and serially diluted, with 100 µl spread
on TSA plates to determine the CFU for each isolate.
48-h biofilms were treated with 200 ml of diluted phage lysate
at two different MOIs, of 1.0 and 0.1. Quantification of biofilm
biomass and viable cell counts following exposure to phage for 6
and 24 h was performed as described above.
Phage Genome Sequencing
Isolation of Phage Genomic DNA
PhagegenomicDNAwasextractedbyaphenol/chloroform/isoamyl
alcohol (25:24:1 [v/v])method using 1.5ml of lysate (107 to 109 pfu/
ml). Lysates were centrifuged at 10,000g for 10min at 4°C, and 1-ml
supernatant was transferred into a fresh microfuge tube and treated
with DNase I (10 ml of 1 mg/ml DNase I) and RNase A (4 ml of 12.5
mg/ml RNase A). 1 ml of phenol (pH 10) was added to each tube,
before vortexing for 30 s, and centrifugation at 10,000g for 10min at
4°C.The aqueous layerwas removed to a fresh tube and1mlphenol/
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TABLE 1 | Details of Staphylococcus aureus isolates used in this study.
Isolate ST CC MRSA Country Year Reference Isolate ST CC MRSA Country Year Reference Isolate ST CC MRSA Country Year Reference
H462 1 1 N UK 1997 (Avrani and Lindell, 2015) ARI7 22 22 Y UK 2007 (Berryhill et al., 2021) D97 55 N UK 1997 (Beeton et al., 2015)
NL0118512 1 1 N Netherlands 1999 (Bankevich et al., 2012) F86956 22 22 Y UK 2007 (Berryhill et al., 2021) D318 57 30 N UK 1997 (Beeton et al., 2015)
BTN2164 1 1 N UK 1999 (Cui et al., 2017a) H43162 22 22 Y UK 2008 (Berryhill et al., 2021) D508 58 15 N UK 1997 (Beeton et al., 2015)
HT2001-254 1 1 Y USA 2001 (Dickey and Perrot, 2019) H91491 22 22 Y UK 2007 (Berryhill et al., 2021) D535 59 N UK 1997 (Beeton et al., 2015)
A93-0066 5 5 Y France 1993 (Adriaenssens and Brister,
2017)
HO50960412 22 22 Y UK 2005 (Berryhill et al., 2021) D551 59 N UK 1997 (Beeton et al., 2015)
FIN61974 5 5 Y Finland 2002 (Adriaenssens and Brister,
2017)
HO5322054809 22 22 Y UK 2005 (Berryhill et al., 2021) D473 69 1 N UK 1997 (Beeton et al., 2015)
H157 5 5 N UK 1997 (Avrani and Lindell, 2015) HO72300407/05 22 22 Y UK 2007 (Berryhill et al., 2021) CDCUSA700 72 8 Y USA 1998 (Chatterjee and Otto, 2013)
AR110735 5 5 Y Ireland 1993 (Bankevich et al., 2012) HO73740468/05 22 22 Y UK 2007 (Berryhill et al., 2021) SWEDEN8890/99 80 80 Y Sweden 1999 (Adriaenssens and Brister,
2017)
BK519 5 5 Y USA 1991 (Bankevich et al., 2012) M81008 22 22 Y UK 2007 (Berryhill et al., 2021) HT2002-0664 80 80 Y France 2002 (Dickey and Perrot, 2019)
NJ992 5 5 Y USA 2002 (Bankevich et al., 2012) T27706 22 22 Y UK 2008 (Berryhill et al., 2021) HT20040991 80 80 Y France 2004 (Dickey and Perrot, 2019)
D10 5 5 N UK 1997 (Beeton et al., 2015) T50530 22 22 Y UK 2007 (Berryhill et al., 2021) BK1563 88 Y USA 1991 (Bankevich et al., 2012)
CDC-USA800 5 5 Y USA 1998 (Chatterjee and Otto, 2013) W44936 22 22 Y UK 2008 (Berryhill et al., 2021) HT2001-0634 93 93 Y Australia 2001 (Dickey and Perrot, 2019)
BTN2242 5 5 N UK 2002 (Cui et al., 2017a) 370.07 22 22 Y UK 2007 (Berryhill et al., 2021) HT2002-0635 93 93 Y Australia 2002 (Dickey and Perrot, 2019)
C56 6 5 N UK 1997 (Avrani and Lindell, 2015) 99ST18131 22 22 Y Australia 1999 (Berryhill et al., 2021) H560 121 N UK 1998 (Avrani and Lindell, 2015)
E228 8 8 N Denmark 1957 (Alves et al., 2014) RH06000061/09 22 22 N UK 2000 (Brandt et al., 1999) D139 145 N UK 1997 (Beeton et al., 2015)
99ST22111 8 8 Y Australia 1997 (Bankevich et al., 2012) BTN1626 22 22 Y UK 2002 (Cui et al., 2017a) FIN62305 156 Y Finland 1990 (Adriaenssens and Brister,
2017)
EMRSA13 8 8 Y UK 1999 (Bankevich et al., 2012) C49 23 22 N UK 1997 (Avrani and Lindell, 2015) D22 182 N UK 1997 (Beeton et al., 2015)
EMRSA2 8 8 Y UK 1999 (Bankevich et al., 2012) D279 25 N UK 1997 (Beeton et al., 2015) CAN6428-011 188 1 N Canada 2002 (Bankevich et al., 2012)
EMRSA6 8 8 Y UK 1999 (Bankevich et al., 2012) H118 28 N UK 1997 (Avrani and Lindell, 2015) D470 207 N UK 1997 (Beeton et al., 2015)
EMRSA7 8 8 Y UK 1999 (Bankevich et al., 2012) CUBA4030 30 30 N Cuba 2000 (Bankevich et al., 2012) NOT116 227 N UK 2000 (Brandt et al., 1999)
NL010548-1 8 8 N Netherlands 1999 (Bankevich et al., 2012) C390 31 30 N UK 1997 (Avrani and Lindell, 2015) WW2594/97-2 228 5 Y Germany 1997 (Adriaenssens and Brister,
2017)
D137 8 8 N UK 1997 (Beeton et al., 2015) H399 33 30 N UK 1997 (Avrani and Lindell, 2015) GERMANY131/98 228 5 Y Germany 1998 (Bankevich et al., 2012)
NOT110 8 8 N UK 2000 (Brandt et al., 1999) C160 34 30 N UK 1997 (Avrani and Lindell, 2015) CDC16 231 5 Y USA 1998 (Chatterjee and Otto, 2013)
CDC-USA300 8 8 Y USA 1998 (Chatterjee and Otto, 2013) MRSA252FKmut 36 30 Y UK 2013 (Abedon, 1992) 99.3759.V 235 5 Y UK 2002 (Bankevich et al., 2012)
15981 8 8 N Spain 2003 (Cui et al., 2017b) FIN75916 36 30 Y Finland 1996 (Adriaenssens and Brister, 2017) 91-4990 239 8 Y Netherlands 1991 (Bankevich et al., 2012)
H169 9 1 N UK 1997 (Avrani and Lindell, 2015) UK96/32010 36 30 Y UK 1996 (Adriaenssens and Brister, 2017) EMRSA11 239 8 Y UK 1999 (Bankevich et al., 2012)
D295 9 1 N UK 1997 (Beeton et al., 2015) H119MRSA 36 30 Y UK 1997 (Avrani and Lindell, 2015) EMRSA4 239 8 Y UK 1999 (Bankevich et al., 2012)
D316 11 12 N UK 1997 (Beeton et al., 2015) H325 36 30 N UK 1997 (Avrani and Lindell, 2015) FFP200 239 8 Y Portugal 1996 (Bankevich et al., 2012)
H117 12 12 N UK 1997 (Avrani and Lindell, 2015) MRSA252 36 30 Y UK 1997 (Avrani and Lindell, 2015) EMRSA9 240 8 Y UK 1999 (Bankevich et al., 2012)
D329 12 12 N UK 1997 (Beeton et al., 2015) EMRSA16 36 30 Y UK 1999 (Bankevich et al., 2012) SWEDEN408/99 246 8 Y Sweden 1999 (Adriaenssens and Brister,
2017)
H402 13 N UK 1997 (Avrani and Lindell, 2015) NottmA 36 30 Y UK 2000 (Brandt et al., 1999) FRA97393 247 8 Y France 2002 (Adriaenssens and Brister,
2017)
C154 14 15 N UK 1997 (Avrani and Lindell, 2015) NottmA2 36 30 N UK 2000 (Brandt et al., 1999) 82MRSA 247 8 Y UK 1997 (Avrani and Lindell, 2015)
C357 15 15 N UK 1997 (Avrani and Lindell, 2015) 03.1791.F 36 30 Y UK 2003 (Centers for Disease Control and Prevention,
2002)
EMRSA5 247 8 Y UK 1999 (Bankevich et al., 2012)
H291 18 15 N UK 1997 (Avrani and Lindell, 2015) 06.9570.L 36 30 Y UK 2006 (Centers for Disease Control and Prevention,
2002)
EMRSA8 250 8 Y UK 1999 (Bankevich et al., 2012)
D17 20 N UK 1997 (Beeton et al., 2015) 07.1227.Z 36 30 Y UK 2007 (Centers for Disease Control and Prevention,
2002)
KD12168 250 8 Y UK 1965 (Bankevich et al., 2012)
98/10618 22 22 Y UK 1998 (Adriaenssens and Brister,
2017)
07.1696.F 36 30 Y UK 2007 (Centers for Disease Control and Prevention,
2002)
27969 398 398 Y UK 2012 N/A
SwedenAO9973 22 22 Y Sweden 1999 (Adriaenssens and Brister,
2017)
07.2449.K 36 30 Y UK 2007 (Centers for Disease Control and Prevention,
2002)
09.4620.V 398 398 Y UK 2012 N/A
WW1678/96 22 22 Y Germany 1996 (Adriaenssens and Brister,
2017)
07.2496.L 36 30 Y UK 2007 (Centers for Disease Control and Prevention,
2002)
09.6440.M 398 398 Y UK 2012 N/A
C101 22 22 N UK 1997 (Avrani and Lindell, 2015) 07.2589.M 36 30 Y UK 2007 (Centers for Disease Control and Prevention,
2002)
11.1299.J 398 398 Y UK 2012 N/A
C720 22 22 Y UK 1998 (Avrani and Lindell, 2015) 07.2880.V 36 30 Y UK 2007 (Centers for Disease Control and Prevention,
2002)
11.2530.K 398 398 Y UK 2012 N/A
H182MRSA 22 22 Y UK 1997 (Avrani and Lindell, 2015) 07.3841.N 36 30 Y UK 2007 (Centers for Disease Control and Prevention,
2002)
11.3281.H 398 398 Y UK 2012 N/A
H65 22 22 N UK 1998 (Avrani and Lindell, 2015) 07.6636.Y 36 30 Y UK 2007 (Centers for Disease Control and Prevention,
2002)
11.4910.K 398 398 Y UK 2012 N/A
EMRSA15-90 22 22 Y UK 1990 (Bankevich et al., 2012) 07.6659.K 36 30 Y UK 2007 (Centers for Disease Control and Prevention,
2002)
11.5252.H 398 398 Y UK 2012 N/A
NL011399-5 22 22 N Netherlands 1999 (Bankevich et al., 2012) 07.7206.Y 36 30 Y UK 2007 (Centers for Disease Control and Prevention,
2002)
11.5654.T 398 398 Y UK 2012 N/A
403.02 22 22 Y UK 2002 (Berryhill et al., 2021) 97.2483.Hb 36 30 Y UK 1997 (Centers for Disease Control and Prevention,
2002)
12.2167.C 398 398 Y UK 2012 N/A
434.07 22 22 Y UK 2007 (Berryhill et al., 2021) 98.5806.F 36 30 Y UK 1998 (Centers for Disease Control and Prevention,
2002)
12.2539.L 398 398 Y UK 2012 N/A
723.07 22 22 N UK 2007 (Berryhill et al., 2021) USA200 36 30 Y USA 1998 (Chatterjee and Otto, 2013) 12.2732.H 398 398 Y UK 2012 N/A
921.07 22 22 Y UK 2007 (Berryhill et al., 2021) BTN1429 36 30 Y UK 2002 (Cui et al., 2017a) 42-57 398 398 Y UK 2012 N/A
930.02 22 22 Y UK 2002 (Berryhill et al., 2021) BTN2172 36 30 Y UK 2002 (Cui et al., 2017a) BVCA92 398 398 Y UK 2012 N/A
1018.07 22 22 Y UK 2007 (Berryhill et al., 2021) BTN2292 36 30 Y UK 2002 (Cui et al., 2017a) C7-t011 398 398 Y UK 2007 N/A
1091 22 22 Y UK 2008 (Berryhill et al., 2021) BTN766 36 30 Y UK 2002 (Cui et al., 2017a) C7(P11) 398 398 Y UK 2007 N/A
729192 22 22 Y UK 2007 (Berryhill et al., 2021) H137 38 30 N UK 1997 (Avrani and Lindell, 2015) C7(P4) 398 398 Y UK 2007 N/A
98.4823.X 22 22 Y UK 1998 (Berryhill et al., 2021) C253 40 30 N UK 1997 (Avrani and Lindell, 2015) GKP136-53 398 398 Y UK 2012 N/A
AR0650784 22 22 Y Ireland 1993 (Berryhill et al., 2021) C427 42 N UK 1997 (Avrani and Lindell, 2015) h-RVC57276 398 398 Y UK 2012 N/A
ARI10 22 22 Y UK 2007 (Berryhill et al., 2021) FIN76167 45 45 Y Finland 1996 (Adriaenssens and Brister, 2017) m-38-53 398 398 Y UK 2012 N/A


































chloroform/isoamylalcohol (25:24:1) was added, vortexed for 30 s,
and centrifuged at 10,000g for a further 10 min at 4°C. The phenol/
chloroform/isoamylalcohol step was then repeated before DNAwas
precipitated with two volumes of ice-cold absolute ethanol and 1/10
volume of 7.5Mammoniumacetate, and stored at−20°C overnight.
Samples were centrifuged at 10,000g for 20 min at 4°C, and DNA
pellets were washed twice with 1 ml 70% ethanol (v/v), then
resuspended in 100 ml nuclease-free water.
Whole-Genome Sequencing
Libraries of the selected phage DNA samples (input DNA 0.2 ng/ml)
were prepared using the Illumina NexteraXT DNA Sample
Preparation Kit following manufacturer’s instructions. Sequencing
of phage DNA (paired-end 2 × 150 high output) was carried out
using the Illumina NextSeq500 platform at Manchester
Metropolitan University, UK.
Genome Assembly, Annotation, and Comparison
Sequence reads were assembled using SPAdes v3.11 (Bankevich
et al., 2012). All phage assemblies resulted in a single large contig
plus a number of small repeats. The largest contig and their
coverage were assessed and visualized using Bandage (Wick et al.,
2015), individual genome assemblies were analyzed using Artemis
(Rutherford et al., 2000), and the largest scaffolds were compared
to the similarity of previously sequenced genomes using BLASTN.
Based on the similarity between our query sequences and the top
hits (closely related genomes) identified using BLASTn, genome
assemblies of all related phage infecting S. aureus were retrieved
from GenBank (https://www.ncbi.nlm.nih.gov/nuccore) and the
European Nucleotide Archive (ENA) databases in April 2021 to
achieve a final collection of 122 phage genomes.
Genomes were annotated with PROKKA v1.14.6 (Seemann,
2014) using a custom Caudovirales gene database (Michniewski
et al., 2019). Neighbor-joining trees were constructed using min-
hash distances implemented in Mashtree (Katz et al., 2019).
Genome comparisons were made using min-hash implemented
in MASH (Ondov et al., 2016), and the pan-genome analysis tool
Roary v3.13.0 (Page et al., 2015) was used to assess the number of
genes shared by each genome (Page et al., 2015). Phylogenetic
trees were constructed using Archaeopteryx v0.9929 (https://
sites.google.com/site/cmzmasek/home/software/archaeopteryx).
Statistical Analysis
Planktonic and biofilm experiments were performed with a
minimum of three replicates, and these values were used to plot
mean ± standard deviation. Statistical analysis was performed
using GraphPad Prism Version 7.0 software package, data were
analyzed as an ordinary one-way analysis of variance (ANOVA)
and Sidak’s multiple comparison test to determine significance of
results. Results were taken as significantly different by a p value
of < 0.05 unless otherwise stated.
RESULTS
Phage Isolation
The modified S. carnosus strain TM300H and S. aureus strain
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filtered sewage samples over a period of several months. Plaques
were all small in size with most being <1 mm in diameter (n=39)
and the largest being 2 mm. 39 of 46 phages were propagated on
TM300H; however, the remainder (EW20, EW29, EW30, EW41,
and EW44-46) could not reliably infect this strain and were
propagated on S. aureus D239 instead. Phages were named in
accordance with recent guidance on nomenclature with the
designations vB_SauM_EW1 to vB_SauM_EW46 (Adriaenssens
and Brister, 2017) and are henceforth referred to as EW1, EW2…
EW46. The 32 phages isolated previously were propagated on
modified TM300H and were named EW47 to EW78.
Host Range
The host range of the 78 phages was determined by spot test of
lysates against 185 S. aureus isolates (Table 2) in agar overlays.
Bacterial strains were classified as sensitive, intermediately
sensitive, or resistant, depending on plaque morphology —
examples of these are shown in Figure 1. The majority














EW1 80 104 1 56.76% EW40 17 158 10 90.81%
EW2 80 104 1 56.76% EW41 6 124 54 96.76%
EW3 27 149 9 85.41% EW42 6 163 16 96.76%
EW4 59 124 2 68.11% EW43 11 159 15 94.05%
EW5 26 153 6 85.95% EW44 44 112 29 76.22%
EW6 42 137 6 77.30% EW45 36 147 2 80.54%
EW7 48 117 20 74.05% EW46 65 116 4 64.86%
EW8 163 21 1 11.89% EW47 123 62 0 33.51%
EW9 70 110 5 62.16% EW48 60 122 3 67.57%
EW10 59 117 9 68.11% EW49 14 147 24 92.43%
EW11 97 83 5 47.57% EW50 139 41 5 24.86%
EW12 71 112 2 61.62% EW51 15 151 19 91.89%
EW13 82 100 3 55.68% EW52 6 152 27 96.76%
EW14 80 101 4 56.76% EW53 27 149 9 85.41%
EW15 7 119 59 96.22% EW54 16 94 75 91.35%
EW16 69 57 59 62.70% EW55 76 96 13 58.92%
EW17 76 52 57 58.92% EW56 19 119 47 89.73%
EW18 3 98 84 98.38% EW57 16 116 53 91.35%
EW19 70 59 56 62.16% EW58 14 107 64 92.43%
EW20 71 60 54 61.62% EW59 13 101 71 92.97%
EW21 18 109 58 90.27% EW60 12 84 89 93.51%
EW22 26 102 57 85.95% EW61 13 99 73 92.97%
EW23 37 119 29 80.00% EW62 12 94 79 93.51%
EW24 30 139 16 83.78% EW63 12 99 74 93.51%
EW25 46 130 9 75.14% EW64 11 97 77 94.05%
EW26 7 116 62 96.22% EW65 13 107 65 92.97%
EW27 5 126 54 97.30% EW66 12 96 77 93.51%
EW28 19 146 20 89.73% EW67 11 94 80 94.05%
EW29 6 142 37 96.76% EW68 11 97 77 94.05%
EW30 16 158 11 91.35% EW69 10 103 72 94.59%
EW31 19 154 12 89.73% EW70 1 88 96 99.46%
EW32 54 122 9 70.81% EW71 1 83 101 99.46%
EW33 19 160 6 89.73% EW72 5 91 89 97.30%
EW34 36 138 11 80.54% EW73 13 95 77 92.97%
EW35 4 169 12 97.84% EW74 2 76 107 98.92%
EW36 7 164 14 96.22% EW75 8 81 96 95.68%
EW37 14 167 4 92.43% EW76 10 83 92 94.59%
EW38 36 148 1 80.54% EW77 13 89 83 92.97%
EW39 142 41 2 23.24% EW78 10 85 90 94.59%
The phage host range is scored as resistant, intermediate, and susceptible based on the level of clearing on host overlays. Percentage coverage is the cumulative number of isolates that
displayed intermediate and sensitive susceptibility to phage.
Coloured shading has been used to indicate level of resistance (red), intermediate-sensitivity (orange), and sensitivity of the isolate collection to phage infection.
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exhibited a broad host range phenotype with 40 of our 78 phage
capable of infecting over 90% of isolates as determined by their
sensitivity or intermediate-sensitivity to phages in this assay
(Table 2). Fifteen of these were capable of disrupting the
growth of over 95% (178/185) of isolates. Phages EW70 and
EW71 had the broadest host range and were capable of infecting
184 of the 185 isolates. Of the 184 isolates, they could infect 96
(53%), and 101 (55%) were fully susceptible, respectively, that is,
they produced distinct clear plaques. The only phage they could
not infect was a mutant of isolate MRSA252 generated in a
previous study during growth of the isolate in liquid culture with
phage K (Alves et al., 2014).
Time Kill Assays in Planktonic Culture
To investigate the dynamics of phages and their hosts in liquid
culture, we quantified the ability of phages to reduce bacterial
numbers in broth cultures and observed any phage-resistant
mutant emergence. We selected ten of the fourteen phages that
were able to infect > 96% of isolates tested, for time kill
experiments (from Table 2). These were phages EW15, EW18,
EW27, EW29, EW36, EW41, EW52, EW71, EW72, and EW74.
Suspensions of these ten phages were tested against TM300H,
D329, MRSA252, and 15981. These isolates were chosen as they
include the two propagating bacteria used, MRSA252,
a representative of a major MRSA lineage (CC30) and the first
genome sequenced MRSA isolate (Holden et al., 2004) and the
well-studied abundant biofilm producing isolate 15981. Phages
were introduced to growing cultures to achieve a multiplicity of
infection (MOI) of 0.1, and incubated for 19 h with OD600
readings taken every 3 min.
Both EW41 and EW52, propagated on D329 were the only
phage ineffective against TM300H in this planktonic culture assay.
The remaining eight phages were successful in reducing the
growth of TM300H within 4 h following their introduction and
they prevented any observable growth of phage-resistant mutants
after 19 h (Figure 2A). With isolate D329, phages EW27 and
EW29 initially took an hour longer than other phage before having
any effect on the host as seen in Figure 2B. However, both EW27
and EW29 effectively reduced the growth of D329 after 4 and 6 h,
respectively, while preventing the emergence of phage-resistant
mutants. As for phage EW72, it was unsuccessful at depleting
bacterial numbers before phage-resistant mutants emerged after
5 h, although this had an effect on the growth rate of D329 when
compared with controls. Interestingly, an increase in bacterial
density compared with the control was observed in D329
following addition of EW36. Individual growth phases appear
less clearly defined with MRSA252 when challenged with phage
(Figure 2C), which is also observed with strain 15981 (Figure 2D).
FIGURE 1 | Host range assay showing effect of 16 phages against S. aureus strain Fin76167. Plaque formation was scored based on the level of clearing,
(A) Resistant with no disturbance to lawn, (B) Intermediate-sensitivity varied from, B1 Few plaques with slight disturbance to lawn, B2 Substantial turbidity
throughout clear zone, B3 High degree of clearing of with numerous mutant colonies present, to (C) Sensitive with complete clearing of bacterial lawn.
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It is clear that a number of phages could not effectively reduce
bacterial numbers before resistant mutants emerge. A reduced rate
of killing was observed among phage when challenged against
other strains compared with their propagating hosts, decreasing
bacterial numbers at a much more gradual rate, with some phage
such as EW15 taking several hours. Interestingly, phage EW71 and
EW74 appeared to have a bacteriostatic effect on strain 15981 with
no change in absorbance observed for c. 14 h before slowly
increasing (Figure 2D).
As observed in D329, EW36 seemed to have a positive effect
on the growth of MRSA252 when compared with the control, as
a significant increase in OD600 with time was observed. The same
trend was also observed with EW72 on the growth of 15981,
however, only slightly more than the control. Interestingly,
EW52 appeared to have a brief positive effect on the growth
rate of MRSA252 for a period of 2 h when initially introduced to
the wells, followed by a prolonged infection period in which
MRSA252 appeared to increase in concentration momentarily,
before eventually decreasing in bacterial density below the initial
concentration after 15 h. For all three S. aureus isolates used,
phages that were able to successfully reduce the optical density
and prevent bacterial regrowth were able to achieve it within 8 h
relative to controls. Nevertheless, there were a number of phages
including EW15, EW27, EW29, and EW52 that exhibited a lower
degree of bacteriolytic ability against their hosts, taking up to ~13 h
to have any inhibitory and bactericidal effect on the bacteria.
Isolate 15981 rapidly evolved resistance to phages EW18 and
EW52. However, phage EW52 was successful in reducing
bacterial density eventually, whereas phage EW18, moderately
reduced growth of 15981 but elicited resistant mutants. Strain
15981 was found to be the most resistant to phage infection
killing in this assay. Reductions to growth were at a much lower
rate compared to other hosts and the appearance of phage-
resistance was observed in each experiment. Phage EW41 was
the most effective at inhibiting the growth of all three S. aureus
isolates, decreasing cell densities rapidly, within 2 h following
phage application. However, as EW41 was isolated and
propagated on D329 because it could not be propagated on
TM300H, it is not surprising that it had little or no effect on
TM300H in this assay.
S. aureus Biofilms
The two most common MRSA lineages in the UK have MLST
sequence types (ST) 22 and 36 and these currently have global
distributions (Holden et al., 2004; Holden et al., 2013). We
selected isolates from these lineages to examine their biofilm
forming properties and susceptibility to phages as these
genotypes are the most common in our collection. We
compared the biofilm densities produced by 43 ST22, and 27
ST36 isolates after 48 h by measurement of absorbance at OD590
A B
C D
FIGURE 2 | Time-kill curve of four mid-exponential phase planktonic S. aureus strains by ten different phages at a multiplicity of infection (MOI) of 0.1. Absorbance
readings at 600 nm were taken using a plate reader every 30 min for 19 h while shaking at 37°C, three independent experiments were performed in total.
(A) Modified S. carnosus isolate TM300H; (B) S. aureus isolate D329, (C) S. aureus isolate MRSA252, and (D) S. aureus isolate 15981.
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following CV staining. We found considerable variation within
isolates of these genotypes (Supplementary Figure 1) with an
obvious dichotomy between relatively little biofilm produced by
most ST22 isolates compared to those of ST36. This can be seen
by visual inspection of stained biofilms from the four most
proficient biofilm producing isolates from each ST with ST36
isolate biofilms being generally darker stained than those of ST22
(Supplementary Figure 2).
We used the same ST22 isolates; ARI10, WW44936, 1018.07,
and HO5322054809 and ST36 isolates; 07.1696.F, 06.9570.L,
07.1227.Z, and 07.2880.V (see Table 1 for details on isolates)
to examine the relationship between biofilm biomass and viable
cell count. We compared OD590 readings of CV-stained 48 h
mature biofilms for these eight isolates and compared these to
viable cell counts. Supplementary Figure 3 shows that the
variation in biofilm biomass between strongest and weakest
biofilm formers does not necessarily correlate to the number
of viable cells present. All isolates had approximately similar
numbers of cells in their biofilms but there was markedly
greater variation within OD590 readings for some isolates.
ST22 isolates ARI10 and WW936 produced significantly
more CV-stained biofilm than 1018.07 and 370.07 and
similarly for ST36 isolates 07.1696.F and 06.9570.L produced
much more CV-stained biofilm than the other two isolates of
this genotype.
ST22 strains displayed a propensity to form moderately
adhered biofilms that had significantly lower ODs than the
best ST36 biofilm formers, yet they had consistently higher cell
counts — similar to those values observed from ST36 isolates.
The biofilms produced by S. aureus were found at the air-biofilm
interface and as large aggregates at the solid-liquid interface at
the base of microtiter plate wells.
Effect of Phages on 48 h Biofilms
We selected four phages (EW27, EW36, EW41, and EW71) for
analysis of biofilm reduction on the basis of; i) their broad host
range against study isolates (Table 2) and ii) rapidly lytic
characteristics in planktonic culture and observed lack of
resistant-mutant selection (Figure 2). Each of these four
phages was added to 48 h biofilms at an MOI of 0.1 or 1.0 and
viable cell counts and OD600 readings of CV-stained biofilms
were performed after 6 and 24 h following phage application.
Biofilm readings for each phage and corresponding viable cell
counts are presented in Supplementary Figures 4–7 and biofilm
readings summarized in Table 3.
EW27
Viable cell counts recovered from each EW27 phage-treated
biofilm for all ST22 and ST36 isolates except for isolate
07.2496.L, were significantly reduced (p < 0.001) following a 6-
h exposure to EW27 when compared to untreated biofilm
controls (Table 3 and Supplementary Figure 4). However,
following an initial decrease in CFU/ml after 6 h, an increase
in bacterial concentration can be seen across all phage-treated
ST22 isolates after 24 h, suggesting that resistance to phage had
occurred within that time. There was no significant difference
between CFU counts from wells treated with phage for 6 and
24 h (p < 0.05). When considering the overall biofilm biomass
following phage exposure and CV staining, results revealed
phage EW27 was highly effective at reducing the biofilms
produced by all ST22 and ST36 strains. For EW27 treated
ST36 isolates, biofilm biomass significantly increased in isolates
07.1696.F, 06.9570.L, and BTN 2172 using both MOI 1 and 0.1
(p < 0.05), despite a minor reduction in bacterial numbers after
24-h treatments compared to 6 h. Following treatment of
EW27 after both timepoints, EW27 at a MOI of 0.1 proved
to be the most effective at both reducing bacterial cells and
biofilm biomass for almost all ST22 and ST36 strains.
EW36
Phage EW36 produced significant reductions in biofilm biomass
for all study isolates except for 07.2496.L at both MOIs (p < 0.01),
with MOI 0.1 proving to be most effective (Table 3 and
Supplementary Figure 5). For both ST22 and ST36, no
increase to biofilm density was observed from 6 to 24 h,
suggesting that phage EW36 successfully disrupted biofilms
preventing regrowth. This is further supported by the greater
reduction in viable cell counts when biofilms were treated
for 24 h. Interestingly, the populations of viable bacteria
recovered from each biofilm produced by the four ST22 and
ST36 isolates were found to be higher in wells treated by
phage EW36 at MOI 0.1, despite producing lower absorbance
readings than biofilms treated with a higher titer of phage at
a MOI 1. EW36 was able to reduce viable cell numbers
for both ST22 and ST36 isolates by at least one-log after 6 h
and two-logs after 24 h at anMOI 0.1. With biofilms treated at an
MOI 1, two-log reductions were observed after 6 h and three-log
reductions after 24 h.
EW41
Significant reductions (p < 0.01) in biofilm biomass were
observed for all ST22 and ST36 isolates tested with phage
EW41 except for isolate 370.07 where two-log reductions in
cells recovered and 60% to 93% reductions in biofilm biomass
were observed after 6 h treatment (Table 3 and Supplementary
Figure 6). Interestingly, phage EW41 had the least effect in
reducing biofilm biomass of isolate W449 36 after 6 h —
reducing it by roughly 22% at an MOI 1 and 19% at an MOI
0.1; however, viable cell counts were relative to all other isolates
and two-log reductions were observed across both time points.
Furthermore, biofilm biomass and viable cell counts recovered
from the biofilms challenged with EW41 after 24 h produced
levels similar to 6 h exposure. Phage EW41 was able to further
reduce biofilm levels of W449 36 by ~85% when exposed for
24 h. ST36 biofilms challenged with phage EW41 for 24 h
produced higher levels of biofilm biomass and increase in cells
recovered by up to one-log when compared to 6 h exposure,
suggesting regrowth had occurred within that time. Across all
ST22 and ST36 isolates, both biofilm biomass and viable cells
recovered were consistently lower in wells challenged with EW41
at an MOI 0.1 when compared with MOI 1, although this was
not significant.
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EW71
Phage EW71 was the most effective of the four in reducing
biofilm density and viable cell numbers (Table 3 and
Supplementary Figure 7). Phage EW71 was effective at
reducing (p < 0.01) biofilm biomass after 6 h treatment while
greatly limiting the amount of regrowth after 24 h. Furthermore,
phage EW71 was successful in reducing the number of viable
cells by up to three-logs after 6 h, and continued to reduce after
24 h treatment by up to four logs versus controls. Biofilm
densities of ST22 following treatment of EW71 after 6 h
ranged from 63% to 87% while consequently preventing the
regrowth of all four ST22 hosts after 24 h, further reducing
biofilm densities. Greater reductions in biofilm densities were
also observed when ST36 isolates were challenged with phage
EW71 with OD590 values reduced by 59 95% after 6 h.
Interestingly, a marginal increase in absorbance was observed
in across all four ST36 biofilms when exposed to phage for 24 h.
However, increases to viable cell counts were only observed for
07.1696.F and 07.2496.L suggesting phage resistance and
regrowth had occurred within the two sampling periods. Phage
applied to biofilms at an MOI 1 were found to be the most
effective at reducing viable cell counts within the biofilm after 6
and 24 h exposures; however, biofilm densities were somewhat
higher with this MOI. Even so, biofilm biomasses were
approximately similar across the majority of hosts for both 6-
and 24-h treatments, except for isolate W449 36; however, this
difference was not significant.
Evaluation of Phage Biofilm Assays
Table 3 and Supplementary Figures 4–7 show the percentage
reduction of S. aureus ST22 and ST36 isolate biofilms when
challenged by EW27, EW36, EW41, and EW71 at MOIs of 1 and
0.1 after 6 and 24 h. For all ST22 isolates the median reduction in
biofilm biomass for MOI 1 and MOI 0.1 after 6 h was 59% and
71% respectively, whereas the median reduction for MOI 1 and
MOI 0.1 after 24 h exposure was 72% and 75%, respectively.
Whereas, for ST36 isolates, the median biofilm biomass
reduction for MOI 1 and MOI 0.1 after 6 h was 80% and 79%,
respectively. After 24 h treatment, the median reduction for MOI
1 and MOI 0.1 for ST36 isolates was 75% and 80%, respectively.
Overall, the highest biofilm biomass reductions after 6 and
24 h phage treatments was observed with phages EW41 and
EW71 respectively, with an MOI of 0.1. Although significant
reductions in biofilm biomass was observed when treated with
both MOIs of phage, the greatest reductions across all ST22 and
ST36 isolates after 6 and 24 h exposure was achieved when
biofilms were treated at an MOI 0.1. Although each phage was
able to disperse the biofilms of all study isolates, complete
elimination of cells was not observed across any of the hosts at
either MOI as cells were recoverable when treated with phages
for 6 h and 24 h.
Phage-Resistant Mutants
The morphology of colonies recovered from phage-treated
biofilms were heterogeneous and this was most marked for
isolates treated with phage EW71 as shown in Figure 3.
Phage-resistant mutant isolates recovered from each phage
experiment were found to be resistant to all phage upon spot
testing on agar overlays.
Genomics
We sequenced the genomes of 22 phages with broad host
range based upon spot testing results (Table 2). All are
Myoviruses and members of the Twortvirinae sub-family of the
family Herelleviridae based on BLASTN similarity. To further
investigate the relatedness and taxonomy of our phages we
compared their genomes to the 100 publicly available
Twortvirinae genomes in Genbank (as of April 2021) using the
TABLE 3 | Summary table showing the relative difference in biofilm reduction of study phage at two multiplicities of infection (MOI) against four ST22 and four
ST36 isolates.
ST22 OD590 MOI 1 EW27MOI 0.1 MOI 1 EW36MOI 0.1 MOI 1 EW41MOI 0.1 MOI 1 EW71MOI 0.1
ARI 10 1.2034 -44% -61% -47% -63% -80% -85% -84% -87%
6 h W449 36 1.1929 -71% -78% -77% -78% -22% -19% -75% -68%
1018.07 0.5941 -59% -74% -58% -72% -59% -70% -67% -73%
370.07 0.4381 -43% -68% -52% -63% -43% -69% -63% -76%
ARI 10 1.2034 -58% -55% -81% -82% -82% -83% -87% -86%
24 h W449 36 1.1929 -68% -77% -82% -85% -85% -86% -84% -84%
1018.07 0.5941 -20% -49% -68% -69% -69% -70% -76% -74%
370.07 0.4381 -25% -43% -59% -68% -63% -66% -78% -75%
ST36 OD590 MOI 1 EW27MOI 0.1 MOI 1 EW36MOI 0.1 MOI 1 EW41MOI 0.1 MOI 1 EW71MOI 0.1
07.1696.F 3.0191 -89% -89% -79% -79% -90% -86% -95% -95%
6 h 06.9570.L 2.7274 -75% -60% -81% -80% -71% -74% -91% -92%
BTN 2172 1.0997 -74% -72% -76% -73% -86% -85% -83% -83%
07.2496.L 0.7536 -64% -69% -20% -29% -70% -70% -81% -79%
07.1696.F 3.0191 -77% -80% -88% -90% -86% -89% -89% -95%
24 h 06.9570.L 2.7274 -25% -51% -89% -90% -59% -84% -90% -92%
BTN 2172 1.0997 -30% -57% -73% -78% -83% -68% -77% -83%
07.2496.L 0.7536 -40% -66% -56% -60% -36% -66% -59% -79%
48 h biofilms were challenged with phage for 6 and 24 h, percentages are based on control values.
Colour used to indicate different treatments.
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min-hash algorithm implemented in MASH (Ondov et al., 2016)
to generate distance matrices that were used to construct the
neighbor-joining dendrograms shown in Figure 4. The 22-phage
genomes segregated into three main groups, designated 1 3.
Group 1
This group contains five phages EW15, EW20, EW22, EW27,
and EW41 (shown in red in Figure 4). They share very high
similarity (MASH distances < 1%) with each other, except for
phage EW41 that differs by 1.6% (Supplementary Table 1). It
also has a slightly smaller genome of 132,999 bp compared to the
others which are c.135,800 bp in size. These phages are very
similar to, and cluster with 11 staphylococcal phages of the genus
Silviavirus (Figure 4B). They include the broad host-range
phages Romulus and Remus, proposed as an ideal candidate
phages for human therapy due to their broad host-range and
virulence (Vandersteegen et al., 2013).
Group 2
The largest group in this study contains 11 phages of the genus
Kayvirus based on genomic sequence similarity, with genomes
that share >95% similarity (i.e. < 5% MASH distance) with each
other (Figure 4 and Supplementary Table 1). It contains three
subgroups A, B, and C, and these are colored green in Figure 4.
Group 2A contains phages EW36 and EW42 that are 139,881
and 139,874 bp in length, respectively. Group 2B is made up of
phages EW1, EW2, EW4 that are very similar (>99%) to each
other and EW13 that differs from these by about 1.8% of bases
The first three phages have genomes that are 140,906 bp long,
about 4 kb shorter than that of EW13 at 145,736 bp. Group 2C
comprises phages EW3, EW5, EW6, EW7, and EW9 with
genomes of between 141,953 and 143,288 bp. Their genomes
are >99.5% similarity to each other. Group 2 phages form a
distinct clade on their own in the dendrogram in Figure 4B and
are most closely related to genomes belonging to phages of the
genus Kayvirus that include the species “Staphylococcus phage
MCE-2014” (Alves et al., 2014) and several unclassified
Kayviruses, sharing c.90% sequence similarity. Phage MCE-
2014 (also known as DRA88) was first reported in a study
where it was used in combination with phage K to treat
experimental S. aureus biofilms. The phage K mutant of strain
MRSA252 used here was derived from this study (Table 1).
Group 3
This group contains two closely related subgroups pf phages
whose genomes differ by c.3%. The four group 3A phages in this
group are EW18, EW26, EW29, and EW72 with genomes of 143,
240 to 143,287 bp that are > 99.5% similar to each other. These
cluster most closely with database isolates of the genus Kayvirus
that include the species phiPLA-Rodi whose reference phage,
phiIPLA-RODI, has been used in several studies, including those
involving S. aureus biofilms (Gutierrez et al., 2015; Gonzalez
et al., 2017). The genomes of group 3B phages EW71 and EW74
are 139,939 and 139,896 bp in length respectively, and they
share >99% sequence similarity with each other and with the
genomes of three phages in Genbank from the genus Kayvirus.
These include phage K (Gill, 2014), the most well known of the
staphylococcal phages (Figure 4B) that is commonly included in
staphylococcal phage preparations (O’Flaherty et al., 2005b).
Overall, the genomes of Silviavirus phages of group 1 share
about 25% to 26% DNA sequence similarity to those of group 2
and group 3 Kayvirus phages. Groups 2 and 3 are more similar
with approximately 90% DNA similarity using min-hash
distances (Supplementary Table 1). Supplementary Table 2
lists all annotated genes in the 122 Twortvirinae studied and
shows their presence absence (BLASTP identity > 95%). Group 1
phages had no genes in common with those of groups 2 and 3
using Roary with default parameters. Groups 2 and 3 shared 38
genes common at BLASTP identity > 95% (18% of the 202 genes
in the EW1 genome). No known function could be assigned to 33
FIGURE 3 | Heterogeneous colony phenotypes produced by S. aureus phage-resistant mutants of 07.2496.L and 07.1696.F following exposure to EW71.
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but the core genes comprised a terminase gene, an intron-
encoded endonuclease, a LysM domain-containing protein, a
putative DNA repair protein, and a virion component protein.
The host range of group 1 phages as measured by percentage
of strains able to be infected (coverage) varied from 61.62%
to 97.3%. In group 2 this coverage varied from 56.76% to 96.76%
and in group 3 from 96.22% to 99.46% (Table 2). All three
groups therefore had phages that could infect the great majority,




FIGURE 4 | Neighbor-joining dendrograms based upon min-hash (MASH) distances. (A) unrooted dendrogram of phages EW1-22 showing three major groupings
and subgroupings. (B) Circular dendrogram showing the relatedness of the same phages in relation to 100 Twortvirinae genome assemblies and the phage genera
they represent. Dendrogram is rooted at the midpoint of the longest branch.
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DISCUSSION
Phage therapy has potential for the treatment of many bacterial
diseases, but for most bacterial pathogens, the limited host range
of lytic phages means that empiric use requires the use of
cocktails of different phage strains with varying host ranges
and virulence characteristics. Broad host range, highly virulent
S. aureus phages are relatively easy to isolate, and their use in
phage therapy, especially in Georgia and Poland, has been
associated with a high degree of success. This study confirms
reports of the extremely broad host range of some Myoviridae,
especially some of the Kayviruses and Silviaviruses characterized
here. Two of these Kayviruses, EW70 and EW71, were able to
infect the complete panel of our genetically diverse 185 S. aureus
isolates in agar overlays that included a very wide range of MRSA
and MSSA genotypes. Nine other phages could infect >96% of
isolates, and these comprised three Silviaviruses, two Kayviruses
of a different clade from EW70 and EW71, as well as four others
that are closely related to EW70 and EW71. The broad host range
of S. aureus Myoviruses is in part explained by their sharing a
common receptor that has been found to be the backbone of cell
wall teichoic acids (Xia et al., 2011; Winstel et al., 2013).
In our planktonic assays, all 10 phages were able to infect at
least one of the four S. aureus isolates tested, and five were able to
infect and significantly reduce the growth of two. EW41 was
found to be the most effective under planktonic conditions, as it
immediately reduced bacterial cell numbers preventing the
regrowth of all three S. aureus isolates, yet it had no effect on
the modified S. carnosus isolate. As it was propagated on S.
aureus strain D239 host, its specificity may be more limited
compared to other phages in infecting coagulase-negative
staphylococci. Four phages had no effect on the growth of at
least one of the three S. aureus hosts in liquid culture. However,
phages that were effective were able to prevent the appearance of
resistant mutants throughout the duration of the experiment.
When resistance mutants were observed, the growth rate and
presumably, fitness of these phage-resistant cells was clearly
affected and did not recover to the levels achieved by
uninfected controls. This suggests that resistance to phage
infection was at the expense of growth capacity (Middelboe,
2000; Avrani and Lindell, 2015). Emergence of spontaneous
phage resistance can involve selection of sub-populations with
altered receptor structures that in S. aureus includes wall techoic
acid (Hall et al., 2011; Xia et al., 2011; Avrani and Lindell, 2015).
Fitness costs associated when acquiring phage-resistance, can
cause a variety of structural and morphological changes (Inal,
2003; Ormala and Jalasvuori, 2013). One approach is concealing
surface receptors that phages used as docking sites to adsorb to
their hosts; however, these sites are often used for the uptake of
nutrients (Mizoguchi et al., 2003), thus possibly limiting their
growth and virulence which may be why cell numbers were able
to recover after 24 h treatment compared with 6 h, yet biofilm
densities remained considerably low.
When applied at low concentrations (MOI 0.1), phage must
infect and replicate enough to increase their number to surpass
the rate of replication for the bacterial host. This would explain
why most host isolates continued to grow for at least 1 h
following introduction. In similar studies comparing phage
infection at various MOIs (Abedon, 1992; Beeton et al., 2015;
Cui et al., 2017a), the greater the MOI the more effective the
phage was in the study, which presumably is largely because of
the increased rate of phage collisions and infections, thus leading
to higher densities in viral progeny in a shorter time frame.
The four S. aureus phages used in biofilm studies were
selected based on their lytic potential in spot plate assays and
in liquid culture. All four exhibited generally high efficacy in
effectively reducing biofilm biomass and cell numbers of each S.
aureus isolate after 6 and 24 h. Cell regrowth was detected
following 24 h infection with phage compared to 6 h by at
least one of the hosts suggesting growth of phage-resistant
mutants had occurred, however this was at the expense of
biofilm regrowth. These observations were similar to those
reported in a previous study of S. aureus biofilm (Melo et al.,
2018). The observation of biofilm regrowth and phage resistance
still remains a major issue and is something regularly observed in
biofilms when challenged by single lytic phage that promotes
mutant selection (Drilling et al., 2014). This necessitates a phage
combination approach using phage cocktails or co-
administration with antibiotics to prevent the emergence of
phage-resistant mutant bacteria. Previous studies have made
use of the disruptive ability of phage to reduce biofilm
structures produced by S. aureus and reduce bacterial
populations enough to facilitate the penetration of antibiotics
and eradicate infection (Tkhilaishvili et al., 2018; Dickey and
Perrot, 2019). Previous evidence suggests that the phage
resistance phenotype increases sensitivity to antibiotics and
also results in a loss of fitness (Leon and Bastias, 2015).
Additionally, the application of phage cocktails consisting of
multiple polyvalent phage that target different receptor proteins
to prevent multi-resistance, but also increase the rate of killing,
thus greatly reducing the probability of hosts acquiring resistance
to phage (Gu et al., 2012). The anti-biofilm capabilities and broad
host range demonstrated by the four study phage make them
promising candidates for possible future combination studies.
Previous phage/host studies have demonstrated that by
increasing the concentration of phage-to-bacteria (MOI),
which, essentially increases the rate of collisions between phage
and biofilm cells leads to increased rate of bacterial killing (Gupta
and Prasad, 2011; Lopes et al., 2018). Additionally, greater
reductions could have been facilitated by direct bacterial lysis the
lysis from without effect. However there was no significant
difference between MOI values, suggesting that an increased
phage-to-bacteria ratio offered no advantages in reducing biofilm
biomass, as described previously (Lopes et al., 2018). Overall,
reductions in biofilm biomass (OD590) were generally higher in
biofilms treated at anMOI0.1 (compared to 1) using any of the four
phage after both 6 and 24 h treatments. The effectiveness of the low
MOI demonstrates the self-perpetuating nature of lytic phage to
proliferate in number, therefore only requiring small initial dosing.
Compared to the characteristic smooth, round colonies
phenotypes typically produced by S. aureus, the recovery of
heterogenous morphotypes produced by phage-resistant
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derivatives following phage exposure were regularly detected
during this study, although most commonly observed in
biofilms treated with EW71. Similar irregular-shaped colonies
have been reported in previous studies and are thought to be
caused by a subpopulation within a colony that has reverted back
to a phage-sensitive phenotype, subsequently leading to cell
death as the colony forms (Mizoguchi et al., 2003; O’Flynn
et al., 2007; Kocharunchitt et al., 2009). However, the
observation of “pacman”-like colonies, as seen here, has not
been as well documented and warrants further investigation.
A major consideration in producing phages for human
therapy is the possible presence of induced prophage from
propagating host bacteria. S. aureus isolates typically harbor
several prophages in their genomes and these mediate
horizontal gene transfer and contain virulence genes such as
toxins (Xia and Wolz, 2014). In this study, we found that most
phages could be propagated on an avirulent S. carnosus strain
that could be used to increase the safety of staphylococcal phage
therapeutics in future GMP manufacturing if used in place of
potentially virulent S. aureus hosts.
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ST36 isolates grown in tissue culture microtiter plates over 48 h at 37°C. Biofilms
densities produced were assessed following crystal violet staining, dissolved in 30%
acetic acid, and measured at an OD590. Each assay was performed in triplicate,
data presented as mean values (± standard deviation).
Supplementary Figure 2 | Variation in biofilm production by ST22 (A) and ST36
(B) isolates after 48 h incubation in TSB supplemented with 1% D-(+)-glucose.
Biofilms were visualized following staining with 0.1% crystal violet.
Supplementary Figure 3 | Comparison of biofilm densities of eight S. aureus
isolates assessed by CV staining (A) and corresponding viable cell counts (B).
Supplementary Figure 4 | Effect of phage EW27 on mature biofilms of S. aureus
ST22 (A) and ST36 isolates (B). Static biofilms were initially grown in tissue-culture
microtiter plates for 48 hand challenged with EW36 at a multiplicity of infection of 1
and 0.1 for a period of 6 and 24 h. (A) Biofilms initially stained with crystal violet and
optical density was measured at an absorbance of 590 nm. (B) Viable cells were
recovered from phage treated wells by scratching and dislodging the biofilms from
the surface plate wells and plated out in triplicate. Each assay was performed in
triplicate, data presented as mean values (± standard deviation).
Supplementary Figure 5 | Effect of phage EW36 on mature biofilms of S. aureus
ST22 (A) and ST36 isolates (B). Static biofilms were initially grown in tissue-culture
microtiter plates for 48 h and challenged with EW36 at a multiplicity of infection of 1
and 0.1 for a period of 6 and 24 h. Top Biofilms initially stained with crystal violet and
optical density was measured at an absorbance of 590 nm. Bottom Viable cells
were recovered from phage treated wells by scratching and dislodging the biofilms
from the surface plate wells and plated out in triplicate. Each assay was performed
in triplicate, data presented as mean values (± standard deviation).
Supplementary Figure 6 | Effect of phage EW41 on mature biofilms of S. aureus
ST22 (A) and ST36 isolates (B). Static biofilms were initially grown in tissue-culture
microtiter plates for 48 h and challenged with EW36 at a multiplicity of infection of 1
and 0.1 for a period of 6 and 24 h. Top Biofilms initially stained with crystal violet and
optical density was measured at an absorbance of 590 nm. Bottom Viable cells
were recovered from phage treated wells by scratching and dislodging the biofilms
from the surface plate wells and plated out in triplicate. Each assay was performed
in triplicate, data presented as mean values (± standard deviation).
Supplementary Figure 7 | Effect of phage EW71 on mature biofilms of S. aureus
ST22 (A) and ST36 isolates (B). Static biofilms were initially grown in tissue-culture
microtiter plates for 48 h and challenged with EW36 at a multiplicity of infection of 1
and 0.1 for a period of 6 and 24 h. Top Biofilms initially stained with crystal violet and
optical density was measured at an absorbance of 590 nm. Bottom Viable cells
were recovered from phage treated wells by scratching and dislodging the biofilms
from the surface plate wells and plated out in triplicate. Each assay was performed
in triplicate, data presented as mean values (± standard deviation).
Supplementary Table 1 | Min-hash distances of study phage genomes
expressed as percent.
Supplementary Table 2 | Gene presence or absence in 122 study phage
genomes (BLASTP>95%).4L2_Filename: fcimb.2021.698909_styled.docx
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